dsip list BREAKING: The FDA just reversed theIR 2023 peptide ban. 12 peptides were just pulled from the Category 2 restricted list: 1. BPC-157 2. Thymosin beta-4 fragment (TB-500) 3. Epitalon 4. GHK-Cu (injectable) FDA staff recommends against adding

Quality control testing is carried out at each stage of the manufacturing process, starting with rigorous raw material assessments and continuing through to finished product testing

Future Prospective Due to the severe side effects of chemotherapy drugs and the emergence of tumor cell resistance, the clinical efficacy of chemotherapy drugs is greatly reduced

This prevents the medication from breaking down and losing its effectiveness

In some embodiments, the otic formulation or composition comprises between about 0.01% to about 2% by weight of the viscosity modulating agent(s)

Consistency is key for best results

References Peer Reviewed Sikiric P et al